AZGP1 and intrahepatic cholangiocarcinoma: This study revealed that lenvatinib increases the expression of AZGP1 by activating H3K27Ac at the promoter region of the AZGP1 gene, thus inhibiting ICC cell migration, invasion, and EMT.